EICHOR
● Not Yet Recruiting
An Ultra-short Course of Primaquine for the Radical Cure of Vivax Malaria
Condition: Malaria · Sponsor: Menzies School of Health Research
About this study
Current treatment regimens to prevent relapsing malaria are too long. A shorter higher dose treatment could improve treatment outcomes, but this needs to be balanced against increased risk of side effects. Recent data from a trial in children in Papua New Guinea (PNG) suggests a shortened treatment of 3 days is safe and effective. Our multicentre trial will assess the safety and efficacy of an ultra-short primaquine course. This trial is expected to directly influence global treatment policies.
This description comes directly from the study's public registry record.
Talk to the study team
Kamala Thriemer, Professor · +61889468644 · Kamala.Ley-Thriemer@menzies.edu.au
Hellen Mnjala, MSc · +61889468675 · hellen.mnjala@menzies.edu.au
Always discuss trial participation with your own doctor first.
Locations (5)
| Arba Minch University | Arba Minch, Arba Minch, Ethiopia | — |
| Jimma University | Jimma, Jimma, Ethiopia | — |
| Universitas Sumatera | Bandar Lampung, Lampung, Indonesia | — |
| Aga Khan University, Karachi | Karachi, Thatta, Pakistan | — |
| Papua New Guinea Institute of Medical Research | Port Moresby, Magang, Papua New Guinea | — |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07468526